ROŻ INTERINDIVIDUAL PHENOTYPIC VARIATIONS IN CLL LYMPHOCYTES

D.Rożynkowa, H.Antosz, A.Kulig, Z.M.Rupniewska, J.Kowalewski and M.Kurowska
Laboratory of Human Genetics and Department of Haematology, Medical Academy Lublin, Poland.

CLL peripheral blood lymphocytes were assayed for spontaneous proliferative potential, proliferative responses to the mitogens Phytohaemagglutinin and Staphylococcus Bacteria, Strain Cowan A, and also for differentiation capabilities toward plasmacytoid cells. This functional analysis was performed on separated T and B cells, cultured together or in transmembrane chambers. Results analysed in different patients indicate various sequences of maturation arrest in B lineage cells and offer as well some insight into T cell pathology in chronic lymphocytic leukaemia.

RYN THE ABSENCE OF VIRAL GENES IN MAMMALIAN TUMOUR CELLS INDUCED BY AVIAN SARCOMA VIRUSES

A.Rynditch[1], J. Geryk[2], B.Yatsula[1] and J.Svoboda[2]
[1]Institute of Molecular Biology and Genetics, Academy of Sciences of USSR, Kiev, USSR. [2]Czechoslovak Academy of Sciences, Prague, Czechoslovakia.

The genomes of 6 mouse and hamster cell lines derived from tumours which had been induced by RSV and rASV are characterized by the absence of viral genes. However, these cells retain their oncogenic phenotype when passaged. The deletion of the src gene suggests that sometimes the presence of src is not required for the maintenance of transformation. In some hamster tumour cell lines RSV-LTR and alteration in the c-Kiras gene were detected.

SAN MEASUREMENTS OF LEUKOCYTE ADHERENCE INHIBITION RESPONSE IN BREAST CANCER PATIENTS AS A PROGNOSTIC FACTOR

T.Sanner, H.K.Kotlar, P.Eker, I.Brennhovd, H.Høst and O.Jørgensen
The Norwegian Radium Hospital, Oslo, Norway.

The haemocytometer leukocyte adherence inhibition (LAI) technique was used to study cell-mediated immune activity against breast carcinoma antigens in patients with cancer of the breast. Blood samples were obtained from the patients the day after admission to the hospital. None of the patients tested had been subjected to treatment. In a group of 83 patients in stage I, 74% showed a positive response, among 47 patients in stage II, 64% responded, while only 51% of the 37 patients in stage III and IV responded. Of 86 control persons, only 2 women showed a positive response. All the analyses were performed in a blind manner. Some of the patients have now been followed for up to 7 years after the LAI-measurements and the start of the treatment. The possible prognostic value of LAI-measurements on the patients has been evaluated.

Supported by the Norwegian Cancer Society.
